Uncategorized
FDA, EMA grant Nightstar orphan drug designation for gene therapy to treat choroideremia
Nightstar has received orphan drug designation from the FDA and the European Medicines Agency for a gene therapy to treat choroideremia, according to a press release.The designation will provide regulatory support in development activities such as protocol assistance, reduced fees, tax incentives and market exclusivity for the product upon approval, the release said.